TITLE
BMS_IM101042_Baseline_WB_study

ORGANISM
Homo sapiens

SUMMARY
The goal of this study is to define the molecular signatures of SLE patients at baseline in BMS IM101042 trial. IM101042 (NCT00119678) is a phase IIb, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept vs placebo on a background of oral glucocorticosteroids in the treatment of subjects with systemic lupus erythematosus and the prevention of subsequent lupus flares, sponsored by Bristol-Myers Squibb.

DESIGN
Total RNA from patients with SLE were collected, and profiled together with samples from normal healthy controls.

PLATFORM
GPL13158 [HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate

CITATIONS
Has this study been published? Please login to update or notify GEO .

MICROARRAYP
T

